Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd (NQ: ENLV )

1.410 +0.050 (+3.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102,482
Open 1.290
Bid (Size) 1.250 (2)
Ask (Size) 1.430 (2)
Prev. Close 1.360
Today's Range 1.260 - 1.470
52wk Range 1.150 - 4.590
Shares Outstanding 18,306,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
From Enlivex Therapeutics Ltd
Via GlobeNewswire

Performance

YTD
-57.27%
-57.27%
1 Month
+0.71%
+0.71%
3 Month
-65.69%
-65.69%
6 Month
-44.71%
-44.71%
1 Year
-47.78%
-47.78%

More News

Read More
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Nasdaq Jumps 250 Points; Crude Oil Down 1%
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dow Dips 100 Points; CarMax Earnings Miss Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Nasdaq Gains Over 50 Points; US Producer Prices Increase In March
Via Benzinga
Topics Stocks
Exposures US Equities
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Via ACCESSWIRE
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
Via ACCESSWIRE
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Exposures COVID-19
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.